Janssen’s IMBRUVICA®▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström’s Macroglobulinemia

Media Inquiries: Natalie Buhl, Mobile: +353 (0)85 744 6696, Email: [email protected]

Investor Relations: Lesley Fishman, Phone: +1 732-524-3922, Louise Mehrotra, Phone: +1 732-524-6491




PHEM/IBR/0615/0008
July 2015